
REXN P/E Ratio
P/E Ratio as of Dec 24, 2025: -1.19
Average-1.25
Median-1.22
Minimum-1.45
Maximum-1.15
-1.19
0.03 (2.59%)past month
The P/E ratio for REXN is -1.19 as of Dec 24, 2025. This represents a increase of 48.75% compared to its 12-month average P/E ratio of -0.8. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Rexahn Pharmaceuticals Inc. P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Rexahn Pharmaceuticals Inc.’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Rexahn Pharmaceuticals Inc. to industry peers.
Rexahn Pharmaceuticals Inc. P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Rexahn Pharmaceuticals Inc.’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Rexahn Pharmaceuticals Inc. to industry peers.
REXN P/E Ratio Insights
See Rexahn Pharmaceuticals Inc.’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in REXN
Order type
Buy in
Order amount
Est. shares
0 shares
REXN P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $2.00 | -1.16 |
| Nov 3, 2025 | $2.14 | -1.22 |
| Oct 1, 2025 | $1.80 | -1.02 |
| Sep 2, 2025 | $1.23 | -0.70 |
| Aug 1, 2025 | $1.07 | -0.55 |
| Jul 1, 2025 | $0.9399 | -0.48 |
| Jun 2, 2025 | $1.09 | -0.56 |
| May 1, 2025 | $0.938 | -0.47 |
| Apr 1, 2025 | $0.91 | -0.46 |
| Mar 3, 2025 | $0.9718 | -0.89 |
| Feb 3, 2025 | $1.08 | -0.99 |
| Jan 2, 2025 | $1.26 | -1.16 |
REXN End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -1.19 | +9.17% |
| 2024 | -1.09 | -147.60% |
| 2023 | 2.29 | -176.33% |
| 2022 | -3.00 | +279.75% |
| 2021 | -0.79 | -24.04% |
| 2020 | -1.04 | — |
FAQs About Rexahn Pharmaceuticals Inc. (REXN) P/E ratio
The latest P/E ratio of REXN is -1.19, as of Dec 24, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Rexahn Pharmaceuticals Inc.’s last 12-month average P/E ratio is -0.8, compared to its current P/E ratio of -1.19. This reflects a increase of 48.75%.
Rexahn Pharmaceuticals Inc.’s current P/E ratio of -1.19 is higher than its last 12-month average P/E of -0.8. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Rexahn Pharmaceuticals Inc.’s average P/E ratio over the last 3 years is 0.08. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Rexahn Pharmaceuticals Inc.’s average P/E ratio over the last 5 years is -0.46. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.